0001209191-21-057527.txt : 20210924 0001209191-21-057527.hdr.sgml : 20210924 20210924105048 ACCESSION NUMBER: 0001209191-21-057527 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210923 FILED AS OF DATE: 20210924 DATE AS OF CHANGE: 20210924 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HIGH SUSANNA GATTI CENTRAL INDEX KEY: 0001691005 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 211275283 MAIL ADDRESS: STREET 1: 75 LORIMER ROAD CITY: BELMONT STATE: MA ZIP: 02141 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-09-23 0 0001818794 Dyne Therapeutics, Inc. DYN 0001691005 HIGH SUSANNA GATTI C/O DYNE THERAPEUTICS, INC. 830 WINTER STREET WALTHAM MA 02451 0 1 0 0 Chief Operating Officer Common Stock 2021-09-23 4 S 0 2451 17.22 D 33453 D Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $17.17 to $17.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. Includes 26,928 unvested RSUs. /s/ Richard Scalzo, Attorney-in-Fact 2021-09-24